Sinovac Biotech of Beijing reported its Sabin strain inactivated polio vaccine (sIPV) proved non-inferiority in China Phase III trials. Because the Sinovac vaccine does not contain any live virus, it is considered safer than its competition, oral polio vaccine (OPV) and inactivated polio vaccine (IPV). Two months ago, Sinovac instituted a poison pill plan against a group of investors with a 40% stake in the company. In 2018, outsiders contested Sinovac's management-led slate of directors. Both sides claimed victory, with the outcome being fought in suits and counter-suits, which continue. More details....
Stock Symbol: (NYSE: SVA)
Share this with colleagues:
Original Article: Sinovac Reports Positive Polio Vaccine Results